Literature DB >> 15371652

Bodipy-FL-verapamil: a fluorescent probe for the study of multidrug resistance proteins.

Anna Rosati1, Luigi Candussio, Enrico Crivellato, Fiora Bartoli Klugmann, Tullio Giraldi, Daniela Damiani, Angela Michelutti, Giuliana Decorti.   

Abstract

Most of the substances used as fluorescent probes to study drug transport and the effect of efflux blockers in multidrug resistant cells have many drawbacks, such as toxicity, unspecific background, accumulation in mitochondria. New fluorescent compounds, among which Bodipy-FL-verapamil (BV), have been therefore proposed as more useful tools. The uptake of BV has been evaluated by cytofluorimetry and fluorescence microscopy using cell lines that overexpress P-glycoprotein (P388/ADR and LLC-PK(1)/ADR) or MRP (multidrug resistance-related protein) (PANC-1) and clinical specimens from patients. The effect of specific inhibitors for P-glycoprotein (verapamil and vinblastine) or MRP (MK571 and probenecid) has been also studied. BV intracellular concentrations were significantly lower in the two P-glycoprotein overexpressing cell lines in comparison with the parental lines. In addition, verapamil and vinblastine increased the intracellular concentrations of the dye; MK571 and probenecid, two MRP inhibitors, increased BV levels in PANC-1 cells, that express this protein. These findings were confirmed in clinical specimens from patients. Fluorescence microscopy revealed a faint fluorescence emission in P-glycoprotein or MRP expressing cell lines; however, treatment with specific inhibitors significantly increased the fluorescence. BV is a useful tool for studying multidrug resistance proteins with different techniques such as cytofluorimetry and fluorescence microscopy, but does not discriminate between P-glycoprotein and MRP. In comparison with other classic fluorescent probes, the assay with this dye is extremely rapid, simple, not toxic for cells, devoid of fluorescent background, and can be useful in the clinical settings.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15371652      PMCID: PMC4611116          DOI: 10.1155/2004/576173

Source DB:  PubMed          Journal:  Cell Oncol        ISSN: 1570-5870            Impact factor:   6.730


  5 in total

1.  Direct assessment of P-glycoprotein efflux to determine tumor response to chemotherapy.

Authors:  Gauri Patwardhan; Vineet Gupta; Juowen Huang; Xin Gu; Yong-Yu Liu
Journal:  Biochem Pharmacol       Date:  2010-03-16       Impact factor: 5.858

Review 2.  Imaging the pharmacology of nanomaterials by intravital microscopy: Toward understanding their biological behavior.

Authors:  Miles A Miller; Ralph Weissleder
Journal:  Adv Drug Deliv Rev       Date:  2016-06-04       Impact factor: 15.470

3.  Isolated rafts from adriamycin-resistant P388 cells contain functional ATPases and provide an easy test system for P-glycoprotein-related activities.

Authors:  Karsten Bucher; Camille A Besse; Sarah W Kamau; Heidi Wunderli-Allenspach; Stefanie D Krämer
Journal:  Pharm Res       Date:  2005-03       Impact factor: 4.200

4.  Fluorescent substrates for flow cytometric evaluation of efflux inhibition in ABCB1, ABCC1, and ABCG2 transporters.

Authors:  J Jacob Strouse; Irena Ivnitski-Steele; Anna Waller; Susan M Young; Dominique Perez; Annette M Evangelisti; Oleg Ursu; Cristian G Bologa; Mark B Carter; Virginia M Salas; George Tegos; Richard S Larson; Tudor I Oprea; Bruce S Edwards; Larry A Sklar
Journal:  Anal Biochem       Date:  2013-03-05       Impact factor: 3.365

5.  MRP (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir and zidovudine, from human endothelial cells.

Authors:  Mark Eilers; Upal Roy; Debasis Mondal
Journal:  Exp Biol Med (Maywood)       Date:  2008-06-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.